ProfileGDS5678 / 1416172_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 83% 81% 82% 82% 82% 80% 80% 81% 83% 82% 81% 83% 82% 84% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.9715583
GSM967853U87-EV human glioblastoma xenograft - Control 25.8394281
GSM967854U87-EV human glioblastoma xenograft - Control 35.9433982
GSM967855U87-EV human glioblastoma xenograft - Control 46.1464382
GSM967856U87-EV human glioblastoma xenograft - Control 55.9965982
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.5267480
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.4962280
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.7737781
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.1055483
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.0225282
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.775281
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.0916483
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.92882
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.1845684